Other Events ·
Tempest Therapeutics, Inc. convened a special meeting of stockholders on July 27, 2026, to approve a Certificate of…
TPSTTempest Therapeutics, Inc.
Tempest Therapeutics, Inc. convened a special meeting of stockholders on July 27, 2026, to approve a Certificate of Amendment to replace supermajority voting requirements and permit stockholder action by written consent. The proposal required a 75% affirmative vote. Although a quorum was present with 67.7% of outstanding shares represented, the company failed to secure sufficient votes to approve the measure. Consequently, the meeting was adjourned and will reconvene on August 17, 2026, to allow additional time for voting. The company engaged Sodali & Co. to assist in obtaining adequate votes. Tempest Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic treatments.